accounting for most other cases (9) . Levels of Lp(a) are estimated to be between 70% and 90% heritable with most of the variability in plasma levels currently explained by genetic variation in LPA, the gene encoding apo(a) (10, 11) .
The weight of evidence is that Lp(a) is not elevated specifically in FH (12) (13) (14) . However, elevated Lp(a) has been shown to be an important predictor of ASCVD in FH (13) (14) (15) (16) . The recently developed
SAFEHEART (Spanish Familial Hypercholesterolemia
Cohort Study) Risk Equation, which includes Lp(a) levels, has also been shown to predict ASCVD events in patients with FH with significantly greater accuracy than other conventional cardiovascular disease risk equations (17) .
Nevertheless there is widespread lack of awareness of the conjoint role of FH and Lp(a) in the acceleration of ASCVD, and most cases in the community remain undiagnosed (18) . Cascade screening, that is, the screening of close family members of an index case, is a cost-effective approach for identifying new cases of FH and for preventing ASCVD (19, 20) . Elevated Lp(a) is also a heritable risk factor that is transmitted independently of FH and may be suitable for cascade testing. However, the effectiveness of Lp(a) cascade screening has not been assessed. BIOCHEMICAL ANALYSES. Plasma lipid profiles and Lp(a) concentrations were determined from fasting venous blood samples as previously described (13) .
DNA was extracted from whole blood using established protocols, and FH was diagnosed using a DNA-array-based platform (23) . Briefly, in patients with a clinical diagnosis of FH, genetic analysis was carried out using the LIPOchip platform (Progenika Biopharma, Derio, Spain), a microarray containing the most frequent LDLR, APOB, and PCSK9 FH mutations found in Spain (23) . From June 2008, copy-number variations in the LDLR gene were also included; before this, LDLR copy-number variation analysis was carried out using adapted quantitative multiplex PCR methodology or multiplex ligation-dependent probe amplification (24) . If these genetic analyses did not identify an FH-causing mutation, sequencing within the LDLR (promoter, translated exon sequences, exon-intron boundaries) and APOB (exon 26) genes was carried out (24) . LDL-cholesterol was calculated using the Friedewald formula. Lp(a) was quantified using an isoformindependent assay (Quantia Lp(a) 7K00-01; Tulip Diagnostics, Bambolim, India) run on an Architect autoanalyzer C16000 (Abbott Diagnostics, Lake Forest, Illinois), and was calibrated using the International Federation of Clinical Chemistry (IFCC) reference apo(a) standard (IFCC/SRM 2B); interassay variation was <7% (13).
DEFINITION OF ASCVD. ASCVD was defined as before (13, 17) as the presence of any of the following: There were no major differences in clinical characteristics between relatives of FH probands with elevated Lp(a) and those from FH probands without elevated Lp(a) (Online Table 1 ). Mean Lp(a) levels Ellis et al.
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were not significantly different when comparing individuals with an LDLR and APOB FH mutation (Online Table 2 ). No PCSK9 mutations were detected.
There was no significant difference in the degrees of separation from the proband for relatives screened with the systematic versus opportunistic screening approach (Online Table 3 ).
CASCADE SCREENING FOR FH AND DETECTION OF ELEVATED LP(a). L i p o p r o t e i n ( a )
l e v e l s i n r e l a t i v e s a n d t h e r e l a t i o n s h i p w i t h p r o b a n d c o n c e n t r a t i o n . In the total cohort of screened relatives (N ¼ 2,927), 60.7% had Lp(a) <30 mg/dl, 14.2%
had levels between 30 and 49 mg/dl, 18.5% between 50 and 99 mg/dl, and 6.6% had an Lp(a) level exceeding 100 mg/dl. As expected, on the basis of the mode of inheritance, the Lp(a) concentration of screened relatives was positively associated with that of the proband (p < 0.001) (Figure 1 ) and the degree of separation from the proband (Online Table 4 ). The concordance rate between a diagnosis of FH and elevated Lp(a) among the relatives screened was 54.7%, with a corresponding kappa statistic of 0.128 indicating poor agreement (Online Table 5 ); the gene variants employed to diagnose FH have been described elsewhere (23, 24) . and Lp(a) levels (p < 0.001) were higher in those 
S y s t e m a t i c t e s t i n g : F H p l u s e l e v a t e d L p ( a )
p
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M A R C H 1 2 , 2 0 1 9 : 1 0 2 9 -3 9 therapy, BMI, smoking, and previous history of ASCVD ( Table 3) . Adjusting for these univariate pre- FH follows an autosomal codominant pattern of Values are mean AE SD, n (%), or geometric mean (95% confidence intervals). Bold p values are significant. Elevated Lp(a) is defined as $50 mg/dl. *Ln transformed.
Abbreviations as in Table 1 . There have been several expert guidelines for the detection and management of elevated Lp(a) (4, 22, 28, 29) . These guidelines generally propose Lp(a) ASCVD ¼ atherosclerotic cardiovascular disease; other abbreviations as in Figure 1 . 
